Mizuho upgraded Solventum and Envista, citing a broadening recovery in the dental industry. For Solventum, the firm expects strong third-quarter revenue momentum to continue into 2026, fueled by new products and market share gains. The bank raised its price target to $100 from $85, lifting its 2027 earnings estimate to $6.55 per share.

The upgrade reflects Solventum’s early closing of its $725 million acquisition of Acera Surgical, with up to $125 million in contingent payments. New launches, including pre-filled 3D-printed attachments for Clarity aligners, are driving growth. The company has also gained about 30% of the North American fluoride market since launching its Clinpro varnish in late 2024.

Mizuho moved Envista to Neutral from Underperform, raising its 2027 earnings estimate and price target to $24. The bank sees improving demand and market share gains in higher-margin products, with the Spark clear aligner business reaching profitability in the third quarter of 2025. Revenue growth of 3.6% is now expected for 2026, with modest margin expansion.